Short answer
TransMedics Group, Inc. (TMDX) filed its Q3 2025 10-Q quarterly report on Oct 29, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $144M (up 32.2% year over year) with net income of $24M.
Q3 2025 key financials · XBRL
- Revenue
- $144M
- +32.2% YoY · −8.6% QoQ
- Net income
- $24M
- +476.8% YoY · −30.3% QoQ
- Operating margin
- 16.2%
- Gross margin
- 58.8%
- EPS (diluted)
- $0.66
- +500.0% YoY · −28.3% QoQ
Source: XBRL data from the TransMedics Group, Inc. (TMDX) Q3 2025 10-Q on SEC EDGAR. USD.
TransMedics Group, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: Prolonged U.S. government shutdown impacting FDA, FAA, SEC operations and causing aviation staffing shortages
- Most updated regulatory risk: FDA review and approval timelines may extend due to funding, staffing, policy changes affecting product launches
- Most impactful legal/compliance risk: Potential furloughs and job cuts at federal agencies increasing uncertainty in regulatory processes
- Operational risk: Aviation services disruption from air traffic controller absences affecting logistical support for business operations
- Financial risk: Government shutdown delaying regulatory approvals risking cash flows and prospects through disrupted product development cycles
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other TransMedics Group, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.